CCL3L1 and CCL4L1: Variable gene copy number in adolescents with and without human immunodeficiency virus type 1 (HIV-1) infection

Genes and Immunity

Volumn 8, Issue 3, 2007, Pages 224-231

  Shao, W ^a   Tang, J ^b   Song, W ^a   Wang, C ^a   Li, Y ^b   Wilson, C M ^b,c   Kaslow, R A ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CC CHEMOKINE LIGAND 4; CC CHEMOKINE LIGAND 4 LIKE 1; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CYTOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA LIKE 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; UNCLASSIFIED DRUG;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIPLOIDY; ETHNIC DIFFERENCE; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION CONTROL; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEPTOR BINDING;

ADOLESCENT; BASE SEQUENCE; CASE-CONTROL STUDIES; CHEMOKINES, CC; DNA PRIMERS; FEMALE; GENE DOSAGE; HAPLOTYPES; HIV INFECTIONS; HIV-1; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34247608805     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364378     Document Type: Article

References (56)

1. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998; 392: 565-568.
2. Ward SG, Westwick J. Chemokines: Understanding their role in T-lymphocyte biology. Biochem J 1998; 333: 457-470.
3. Murphy PM. International Union of Pharmacology. XXX Update on chemokine receptor nomenclature. Pharmacol Rev 2002; 54: 227-229.
4. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
5. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108-115.
6. Tang J, Kaslow RA. Polymorphic chemokine receptor and ligand genes in HIV infection. In: Bellamy R (ed). Susceptibility to Infectious Diseases: The Importance of Host Genetics, 1st edn. Cambridge University Press: Cambridge, 2004, pp 185-220.
7. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006; 296: 815-826.
8. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-1815.
9. Mackay CR. CCL3L1 dose and HIV-1 susceptibility. Trends Mol Med 2005; 11: 203-206.
10. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006; 440: 890-895.
11. Meddows-Taylor S, Donninger SL, Paximadis M, Schramm DB, Anthony FS, Gray GE et al. Reduced ability of newborns to produce CCL3 is associated with increased susceptibility to perinatal human immunodeficiency virus 1 transmission. J Gen Virol 2006; 87: 2055-2065.
12. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002; 13: 455-481.
13. Miyakawa T, Obaru K, Maeda K, Harada S, Mitsuya H. Identification of amino acid residues critical for LD78beta, a variant of human macrophage inflammatory protein-1alpha, binding to CCR5 and inhibition of R5 human immunodeficiency virus type 1 replication. J Biol Chem 2002; 277: 4644-4655.
14. Townson JR, Barcellos LF, Nibbs RJ. Gene copy number regulates the production of the human chemokine CCL3-L1 Eur J Immunol 2002; 32: 3016-3026.
15. Howard OM, Turpin JA, Goldman R, Modi WS. Functional redundancy of the human CCL4 and CCLAL1 chemokine genes. Biochem Biophys Res Commun 2004; 320: 927-931
16. Modi WS. CCL3L1 and CCL4L1 chemokine genes are located in a segmental duplication at chromosome 17q12. Genomics 2004; 83 735-738.
17. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307: 1434-1440.
18. Gallo RC, Garzino-Demo A, DeVico AL. HIV infection and pathogenesis: what about chemokines? J Clin Immunol 1999; 19: 293-299.
19. Gonzalez E, Dhanda R, Bamshad M, Mummidi S, Geevarghese R, Catano G et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1α: Impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA 2001; 98: 5199-5204.
20. Tang J, Shelton B, Makhatadze NJ, Zhang Y, Schaen M, Louie LG et al. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002; 76: 662-672.
21. Tang J, Wilson CM, Meleth S, Myracle A, Lobashevsky E, Mulligan MJ et al. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS 2002; 16: 2275-2294.
22. Kostrikis LG, Neumann AU, Thomson B, Korber BT, McHardy P, Karanicolas R et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J Virol 1999; 73: 10264-10271.
23. Gonzalez E, Bamshad M, Sato N, Mummidi S, Dhanda R, Catano G et al. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci USA 1999; 96: 12004-12009.
24. Tang J, Wilson CM, Schaen M, Myracle A, Douglas SD, Kaslow RA. CCR2 and CCR5 genotypes in HIV type 1-infected adolescents: Limited contributions to variability in plasma HIV type 1 RNA concentration in the absence of antiretroviral therapy. AIDS Res Hum Retroviruses 2002; 18: 403-412.
25. Ioannidis JP, Contopoulos-Ioannidis DG, Rosenberg PS, Goedert JJ, De Rossi A, Espanol T et al. Effects of CCR5-Δ32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis. AIDS 2003; 17: 1631-1638.
26. Tang J, Kaslow RA. The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy. AIDS 2003; 17 (Suppl 4): S51-S60.
27. Nolan D, Gaudieri S, John M, Mallal S. Impact of host genetics on HIV disease progression and treatment: New conflicts on an ancient battleground. AIDS 2004; 18: 1231-1240.
28. O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet 2004; 36: 565-574.
29. Silverberg MJ, Smith MW, Chmiel JS, Detels R, Margolick JB, Rinaldo CR et al. Fraction of cases of acquired immundeficiency syndrome prevented by the interactions of identified restriction gene variants. Am J Epidemiol 2004; 159: 232-241.
30. Telenti A, Ioannidis JP. Susceptibility to HIV infection - disentangling host genetics and host behavior. J Infect Dis 2006; 193: 4-6.
31. Modi WS, Lautenberger J, An P, Scott K, Goedert JJ, Kirk GD et al. Genetic variation in the CCL18-CCL3-CCL4 chemokine gene cluster influences HIV type 1 transmission and AIDS disease progression. Am J Hum Genet 2006; 79: 120-128.
32. Oravecz T, Pall M, Norcross MA. Beta-chemokine inhibition of monocytotropic HIV-1 infection. Interference with a postbinding fusion step. J Immunol 1996; 157: 1329-1332.
33. Yang AG, Bai X, Huang XF, Yao C, Chen S. Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci USA 1997; 94 11567-11572.
34. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-673.
35. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM et al. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272: 1955-1958.
36. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD et al. Global variation in copy number in the human genome. Nature 2006; 444: 444-454.
37. Polo S, Veglia F, Malnati MS, Gobbi C, Farci P, Raiteri R et al. Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. AIDS 1999; 13: 447-454.
38. Bubel S, Wilhelm D, Entelmann M, Kirchner H, Kluter H. Chemokines in stored platelet concentrates. Transfusion 1996; 36: 445-449.
39. Baltus T, von Hundelshausen P, Mause SF, Buhre W, Rossaint R, Weber C. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J Leukoc Biol 2005; 78: 435-441.
40. Aukrust P, Muller F, Froland SS. Circulating levels of RANTES in human immunodeficiency virus type 1 infection: Effect of potent antiretroviral therapy. J Infect Dis 1998; 177: 1091-1096.
41. Malnati MS, Tambussi G, Fischetti L, Algeri M, Veglia F, Capiluppi B et al. Analysis of serum and plasma beta chemokines in primary HIV infection (PHI). J Biol Regul Homeost Agents 2000; 14: 75-78.
42. Montano M, Rarick M, Sebastiani P, Brinkmann P, Russell M, Navis A et al. Gene-expression profiling of HIV-1 infection and perinatal transmission in Botswana. Genes Immun 2006; 7: 298-309.
43. Bugeja MJ, Booth DR, Bennetts BH, Guerin J, Kaldor JM, Stewart GJ. Analysis of the CCL3-L1 gene for association with HIV-1 susceptibility and disease progression. AIDS 2004; 18: 1069-1071.
44. Pilotti E, Eviri L, Vicenzi E, Bertazzoni U, Re MC, Allibardi S et al. Post-genomic upregulation of CCL3L1 expression in HTLV-2 infected individuals curtails HIV-1 replication. Blood 2007, in press.
45. Abbott CA, Yu DM, Woollatt E, Sutherland GR, McCaughan GW, Gorrell MD. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem 2000; 267: 6140-6150.
46. Chiravuri M, Agarraberes F, Mathieu SL, Lee H, Huber BT. Vesicular localization and characterization of a novel postproline-cleaving aminodipeptidase, quiescent cell proline dipeptidase. J Immunol 2000; 165: 5695-5702.
47. Rogers AS, Futterman DK, Moscicki AB, Wilson CM, Ellenberg J, Vermund SH. The REACH Project of the Adolescent Medicine HIV/AIDS Research Network: Design, methods, and selected characteristics of participants. J Adolesc Health 1998; 22: 300-311.
48. Wilson CM, Houser J, Partlow C, Rudy BJ, Futterman DC, Friedman LB. The REACH (Reaching for Excellence in Adolescent Care and Health) project: study design, methods, and population profile. J Adolesc Health 2001; 29: 8-18.
49. Fernandez S, Wassmuth R, Knerr I, Frank C, Haas JP. Relative quantification of HLA-DRA1 and -DQA1 expression by real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Eur J Immunogenet 2003; 30: 141-148.
50. Adur J, Uchide T, Takizawa S, Quan J, Saida K. Real-time polymerase chain reaction quantification of gene expression levels of murine endothelin-A and endothelin-B receptors: Gene expression profiles by the standard curve method. J Cardiovasc Pharmacol 2004; 44: S321-S328.
51. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, Leitman SF, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Lancet 1998; 352: 866-870.
52. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998; 282: 1907-1911.
53. Mangano A, Gonzalez E, Dhanda R, Catano G, Bamshad M, Bock A et al. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J Infect Dis 2001; 183: 1574-1585.
54. Song W, Wilson CM, Allen S, Wang C, Li Y, Kaslow RA et al. Interleukin 18 and human immunodeficiency virus type I infection in adolescents and adults. Clin Exp Immunol 2006; 144: 117-124.
55. Wang C, Tang J, Geisler WM, Crowley-Nowick PA, Wilson CM, Kaslow RA. Human leukocyte antigen and cytokine gene variants as predictors of recurrent Chlmydia trachomatis infection in high-risk adolescents. J Infect Dis 2005; 191: 1084-1092.
56. Wang C, Tang J, Crowley-Nowick PA, Wilson CM, Kaslow RA, Geisler WM. Interleukin (IL)-2 and IL-12 responses to Chlamydia trachomatis infection in adolescents. Clin Exp Immunol 2005; 142: 548-554.